Lifestyle Medicine and Atrial Fibrillation in Viet Nam: Risk Factor Management, Stroke Prevention, and Anticoagulation Safety

Lifestyle Medicine and Atrial Fibrillation in Viet Nam: Risk Factor Management, Stroke Prevention, and Anticoagulation Safety

Primary category: Evidence & Clinical Practice

Secondary category: Lifestyle Medicine in Viet Nam

Article type: VLMA Perspective

Last reviewed: October 30, 2026

A person diagnosed with atrial fibrillation may begin exercising regularly, lose excess weight, reduce alcohol consumption, and improve their sleep. After several months, their palpitations may become less frequent, their blood pressure may improve, and they may feel considerably better.

These changes are encouraging, but they can also lead to an important question: if the irregular heartbeat appears to be under control, is medication to prevent a stroke still necessary?

The answer depends on more than how the person feels or whether a recent electrocardiogram shows a normal rhythm.

Atrial fibrillation illustrates both the value and the limits of Lifestyle Medicine. Appropriate changes in health behaviors can reduce arrhythmia burden, improve cardiovascular health, and support long-term disease management. However, fewer symptoms or better rhythm control do not automatically eliminate the risk of stroke or systemic thromboembolism.

For healthcare professionals in Viet Nam, responsible management requires distinguishing between three related objectives: controlling atrial fibrillation and its symptoms, preventing stroke, and minimizing treatment-related harm. These objectives are closely connected, but improvement in one area does not guarantee improvement in the others.

This distinction is particularly relevant following the publication of the 2026 Asia Pacific Heart Rhythm Society guidelines, a comprehensive four-part series published online on October 21, 2026, and formally announced on October 27, 2026.

The guidelines bring together updated recommendations on detection, integrated care, stroke prevention, rate and rhythm control, and lifestyle risk factor management. They also address emerging evidence concerning anticoagulant treatment after apparently successful catheter ablation.

For the Vietnam Lifestyle Medicine Alliance (VLMA), these developments provide an opportunity to examine how evidence-based Lifestyle Medicine can contribute to cardiovascular care while respecting the clinical responsibilities involved in preventing stroke and managing long-term treatment.

Atrial Fibrillation Is More Than an Irregular Heartbeat

Atrial fibrillation is a common cardiac arrhythmia characterized by disorganized electrical activity in the atria and a typically irregular ventricular rhythm.

Some people experience palpitations, fatigue, breathlessness, dizziness, or reduced exercise tolerance. Others have few noticeable symptoms, and the condition may be identified during an examination for an unrelated health concern.

The absence of symptoms does not necessarily indicate a low-risk condition. Atrial fibrillation is associated with an increased risk of ischemic stroke, systemic thromboembolism, heart failure, and other cardiovascular complications.

These risks depend on more than the frequency or intensity of palpitations. Age, previous stroke or transient ischemic attack, hypertension, diabetes, heart failure, vascular disease, and other clinical characteristics influence the likelihood of thromboembolic events.

Underlying structural heart disease and associated medical conditions also affect treatment decisions.

An irregular pulse or a notification from a wearable device may raise suspicion of atrial fibrillation, but diagnosis requires appropriate electrocardiographic evidence interpreted by a qualified healthcare professional.

This distinction has become increasingly important as consumer devices gain the ability to identify possible rhythm abnormalities. A notification indicating an irregular heartbeat is not equivalent to a confirmed diagnosis, and device-detected atrial episodes may require a different clinical assessment from established atrial fibrillation.

The available rhythm recording, episode duration, clinical circumstances, and patient's risk profile can all influence subsequent decisions.

The 2026 Asia Pacific Heart Rhythm Society guidelines address atrial fibrillation through four complementary areas: detection and integrated patient care, stroke prevention, rate and rhythm control, and comprehensive management of lifestyle risk factors and associated medical conditions.

Together, they reinforce a broader understanding of the disease. Atrial fibrillation should not be managed solely as an electrical disturbance requiring restoration of a normal rhythm.

Effective care also requires attention to cardiovascular health, associated conditions, the likelihood of future complications, treatment safety, and the patient's everyday functioning.

Managing Risk Factors Can Improve Atrial Fibrillation Outcomes

Several potentially modifiable factors contribute to the development, progression, and clinical burden of atrial fibrillation.

These include excess body weight, hypertension, physical inactivity, tobacco use, harmful alcohol consumption, sleep-disordered breathing, and metabolic disease.

These conditions frequently coexist. Someone with atrial fibrillation may also have obesity, poorly controlled hypertension, type 2 diabetes, and suspected obstructive sleep apnea. Treating the arrhythmia while leaving these associated problems inadequately managed may limit the overall effectiveness of care.

Part IV of the 2026 Asia Pacific Heart Rhythm Society guidelines specifically addresses comprehensive lifestyle risk factor and comorbidity management. It recognizes these interventions as integral components of atrial fibrillation care alongside appropriate rate or rhythm control and stroke prevention.

Weight management provides an important example.

In people with atrial fibrillation who have overweight or obesity, sustained weight reduction can improve symptoms and reduce arrhythmia burden, recurrence, or progression.

Studies involving structured risk factor management have demonstrated meaningful benefits, particularly when weight reduction is maintained rather than followed by substantial fluctuations.

The 2026 regional guidelines recommend targeting a reduction of more than 10% of initial body weight in appropriate patients with overweight or obesity as part of a comprehensive risk factor management program. This is a Class I recommendation supported by Level A evidence.

However, it should not be interpreted as a weight-loss requirement for every person with atrial fibrillation.

An older patient with frailty, low muscle mass, or nutritional depletion may require a different approach from someone living with obesity. In some individuals, preserving muscle strength, physical function, and nutritional adequacy may be more important than reducing body weight.

The guidelines also discuss emerging evidence concerning medicines used to treat obesity, particularly glucagon-like peptide-1 receptor agonists.

These medicines can produce substantial weight reduction and improve selected cardiometabolic outcomes. Observational studies and some emerging clinical research suggest possible benefits concerning atrial fibrillation recurrence in certain populations.

However, the 2026 guideline recommendation is conditional, and evidence of a direct, consistent antiarrhythmic benefit across the entire drug class remains incomplete.

These medicines should therefore not be presented as established atrial fibrillation treatments for everyone. Their use requires appropriate clinical indications, consideration of benefits and harms, and compliance with the regulatory status of specific products.

Blood pressure management is another essential component.

Hypertension contributes to cardiovascular disease and is included in established stroke-risk assessment models. Effective blood pressure control may contribute to better atrial fibrillation outcomes and reduce broader cardiovascular risks.

It can also address an important modifiable bleeding risk in patients receiving anticoagulant treatment.

Diabetes, heart failure, chronic kidney disease, and other associated conditions require appropriate management within the broader cardiovascular care plan.

For Lifestyle Medicine, the goal is not simply to achieve a particular weight or blood pressure measurement. It is to support sustainable improvements in health while ensuring that established arrhythmia treatment and stroke prevention remain appropriate.

Exercise Can Help, but the Amount Must Fit the Patient

Physical activity is an established component of cardiovascular health, and evidence supports its contribution to atrial fibrillation management.

The 2026 Asia Pacific Heart Rhythm Society guidelines recommend aerobic exercise of up to 210 minutes per week to improve cardiorespiratory fitness and reduce atrial fibrillation burden, recurrence, and symptoms.

This is a Class I recommendation supported by Level A evidence, reflecting clinical studies showing that appropriately prescribed aerobic exercise can improve functional capacity and rhythm-related outcomes in selected patients.

However, the recommended amount should not become a compulsory target for everyone.

A person with well-controlled atrial fibrillation and good exercise tolerance may be suitable for a different program from someone with symptomatic heart failure, uncontrolled ventricular rates, significant valvular disease, or substantial physical limitations.

Exercise selection, intensity, duration, and progression should reflect the person's clinical condition, current treatment, physical capacity, and response to activity.

Concerning symptoms during exertion also require attention. Chest discomfort, near-fainting, marked breathlessness, or unexpected deterioration may warrant medical assessment before exercise is continued or intensified.

There is an additional distinction between regular therapeutic exercise and prolonged, high-volume endurance training.

Although physical inactivity contributes to cardiovascular risk, observational research has associated very high levels of endurance exercise with an increased risk of developing atrial fibrillation in certain populations.

This does not mean that endurance exercise is inherently harmful or that people with atrial fibrillation should avoid physical activity. It means that progressively greater exercise intensity or duration is not necessarily beneficial without limit.

For many patients, maintaining a suitable program over time may be more valuable than attempting to reach an ambitious target immediately.

Walking, cycling, or other aerobic activities may be appropriate depending on individual circumstances. Some patients may benefit from supervised exercise or cardiac rehabilitation, particularly when associated cardiovascular conditions or uncertainty about exercise safety are present.

The program should also consider work schedules, family responsibilities, access to suitable environments, and confidence in exercising safely.

Lifestyle Medicine can contribute through behavior-change support, individualized planning, and continued follow-up.

Nevertheless, improvements in exercise tolerance or atrial fibrillation symptoms do not independently establish that antiarrhythmic medication, catheter ablation, or anticoagulation is no longer necessary.

Alcohol, Sleep, and Psychological Health Have Different Clinical Implications

Alcohol consumption is a potentially modifiable factor in atrial fibrillation.

Both acute excessive drinking and chronic alcohol exposure can increase atrial fibrillation risk. Randomized clinical research has demonstrated that abstaining from alcohol can reduce arrhythmia recurrence in some people with established atrial fibrillation.

The 2026 Asia Pacific Heart Rhythm Society guidelines encourage complete alcohol abstinence where feasible.

When abstinence is not achievable, the guidelines recommend reducing consumption to no more than 30 grams of ethanol per week.

This recommendation is specific to atrial fibrillation management. It should not be interpreted as establishing a universally safe amount of alcohol for general health or suggesting that people who do not drink should begin drinking.

For healthcare professionals in Viet Nam, counseling should consider the actual quantity and frequency of alcohol consumed rather than rely only on the number of glasses or drinking occasions.

Sleep-related conditions require a different clinical approach.

Obstructive sleep apnea is frequently associated with atrial fibrillation and may contribute to atrial remodeling through intermittent hypoxia, changes in autonomic function, and other physiological mechanisms.

Patients with relevant symptoms or risk factors may require assessment for sleep-disordered breathing, particularly when rhythm-control treatment is being considered.

However, recognizing an association between obstructive sleep apnea and atrial fibrillation is not the same as demonstrating that treating sleep apnea reliably prevents arrhythmia recurrence.

Observational studies have suggested that continuous positive airway pressure treatment may reduce atrial fibrillation recurrence in some populations, but randomized controlled trials have not consistently confirmed this benefit.

The 2026 Asia Pacific Heart Rhythm Society guidelines acknowledge this uncertainty.

Obstructive sleep apnea should be assessed and treated when clinically indicated, including for its broader health consequences. Treatment should not, however, be promised as a reliable means of preventing atrial fibrillation recurrence in every patient.

Psychological health also deserves attention.

Someone with recurrent palpitations may become anxious about another episode. Another person may worry about stroke, long-term medication, bleeding complications, or the possibility of further cardiac procedures.

These concerns can affect quality of life, treatment participation, and confidence in everyday activities.

Appropriate psychological assessment and support may help patients manage distress and participate more effectively in their care. However, atrial fibrillation should not be reduced to a condition caused by stress, and psychological interventions cannot replace necessary cardiac evaluation.

The clinical importance of these lifestyle-related factors lies in understanding their different contributions rather than assuming that they all have identical effects on arrhythmia recurrence, cardiovascular outcomes, or stroke risk.

Fewer Arrhythmia Episodes Do Not Automatically Mean Lower Stroke Risk

One of the most important distinctions in atrial fibrillation management concerns the relationship between rhythm control and stroke prevention.

A patient may experience fewer atrial fibrillation episodes after weight loss, medication, or catheter ablation. They may no longer notice palpitations and may feel that their heart rhythm has returned to normal.

Yet the underlying factors contributing to thromboembolic risk may remain.

The decision to use oral anticoagulation is based primarily on clinical assessment of stroke risk rather than simply on whether the patient currently experiences symptoms.

The 2026 Asia Pacific Heart Rhythm Society guidelines recommend the CHA₂DS₂-VASc score for assessing stroke risk in Asian patients with atrial fibrillation.

This scoring system incorporates established clinical factors, including heart failure, hypertension, age, diabetes, previous stroke or transient ischemic attack, vascular disease, and sex.

The 2024 European Society of Cardiology guidelines use a related approach based on the CHA₂DS₂-VA score, which excludes sex as a separate scoring component.

These differences illustrate why scoring systems should be interpreted within the appropriate guideline framework and in conjunction with the patient's clinical circumstances.

A score can help structure decision-making, but it does not replace professional judgment.

Stroke risk is also dynamic.

Someone who has a relatively low estimated risk today may later develop hypertension, diabetes, heart failure, or another relevant condition. Advancing age can independently change the assessment.

The 2026 Asia Pacific Heart Rhythm Society guidelines recommend reassessing stroke risk regularly, at least annually and preferably every four months.

The optimal interval has not been definitively established, and reassessment should also occur when clinical circumstances change.

Another consideration is that atrial fibrillation can recur without noticeable symptoms.

The absence of palpitations does not establish that the patient has remained continuously free from arrhythmia. A reassuring electrocardiogram during a single consultation also cannot exclude intermittent episodes occurring at other times.

For these reasons, symptom improvement should prompt review of the overall care plan rather than an automatic decision to discontinue anticoagulation.

Risk factor management and rhythm control may improve important aspects of cardiovascular health, but stroke prevention requires continuing assessment in its own right.

Safe Anticoagulation Requires Appropriate Treatment and Follow-Up

Oral anticoagulants substantially reduce the risk of ischemic stroke in appropriately selected patients with atrial fibrillation.

These medicines also increase bleeding risk, making careful prescribing, monitoring, and communication essential.

The clinical objective is not simply to avoid bleeding by reducing anticoagulant treatment. It is to provide appropriate protection against thromboembolism while minimizing avoidable treatment-related harm.

The 2026 Asia Pacific Heart Rhythm Society guidelines recommend direct oral anticoagulants in preference to warfarin for most eligible patients with atrial fibrillation.

Important exceptions include patients with mechanical heart valves and those with moderate-to-severe mitral stenosis, particularly rheumatic mitral stenosis, for whom vitamin K antagonist treatment remains necessary.

In patients with atrial fibrillation and rheumatic moderate-to-severe mitral stenosis, warfarin is recommended independently of the usual stroke-risk score.

These distinctions matter because newer anticoagulants are not appropriate for every patient.

For those receiving direct oral anticoagulants, dose selection must follow the approved product information and relevant clinical characteristics.

Kidney function, age, body weight, potential drug interactions, and the particular anticoagulant may influence dosing decisions.

Prescribing a lower dose without an established indication does not necessarily make treatment safer. Inappropriate underdosing may reduce protection against ischemic stroke or systemic thromboembolism.

Patients receiving warfarin require appropriate monitoring of the international normalized ratio and management of relevant medication and dietary interactions.

Direct oral anticoagulants do not generally require routine international normalized ratio monitoring, but they still require clinical follow-up. Renal function, adherence, bleeding symptoms, potential interactions, and changes in medication or health status should be reviewed when appropriate.

The distinction between anticoagulants and antiplatelet medicines must also remain clear.

Aspirin is not an equivalent substitute for indicated oral anticoagulation in atrial fibrillation.

Combining an anticoagulant with aspirin or another antiplatelet medicine can increase bleeding risk and should not be undertaken routinely without a separate clinical indication.

Some patients require combined antithrombotic treatment after an acute coronary syndrome or coronary intervention. Such decisions require individualized assessment of ischemic and bleeding risks, together with an appropriate treatment duration.

Bleeding-risk assessment helps identify concerns such as uncontrolled hypertension, previous bleeding, impaired kidney function, interacting medicines, and harmful alcohol consumption.

The 2026 Asia Pacific Heart Rhythm Society guidelines recommend the HAS-BLED score for bleeding-risk assessment in Asian patients with atrial fibrillation.

Importantly, a high bleeding-risk score should not automatically result in withholding an indicated anticoagulant.

Its principal value is to identify modifiable risk factors and patients who may need closer monitoring, more careful treatment planning, or additional support.

Patient education is another important component of anticoagulation safety.

Unexpected bleeding, blood in the urine, black stools, or other concerning symptoms require appropriate medical assessment. Sudden neurological deficits, severe bleeding, or other acute warning signs require emergency care.

Patients also need to understand why anticoagulants have been prescribed and why consistent treatment matters.

A person who experiences fewer palpitations may reasonably wonder whether continuing medication is necessary. Healthcare professionals should address that question through explanation and reassessment rather than assuming the patient understands the difference between rhythm control and stroke prevention.

Anticoagulation After Cardioversion and Catheter Ablation

Restoration of sinus rhythm can create understandable uncertainty about whether anticoagulant treatment remains necessary.

This question commonly arises after cardioversion or catheter ablation, but the clinical considerations differ according to the procedure, timing, and patient's thromboembolic risk.

Following cardioversion, thromboembolic risk may persist even after a normal rhythm has been restored because of pre-existing atrial thrombus or temporary impairment of atrial mechanical function.

The 2026 Asia Pacific Heart Rhythm Society guidelines recommend that patients with atrial fibrillation lasting more than 24 hours, or of uncertain duration, generally receive at least three weeks of therapeutic anticoagulation before planned cardioversion or undergo an appropriate imaging-guided strategy to exclude atrial thrombus.

Anticoagulation is recommended for at least four weeks after cardioversion, regardless of baseline stroke risk. Longer-term decisions depend on the patient's thromboembolic risk profile.

The management of shorter-duration atrial fibrillation or urgent cardioversion requires individualized assessment according to the clinical circumstances.

For catheter ablation, anticoagulation during the early postprocedural period is also important.

The regional guidelines recommend continuing oral anticoagulation for at least two months after catheter ablation, regardless of the baseline stroke-risk profile.

Long-term treatment after this period involves additional considerations.

Traditionally, major international guidelines have emphasized that long-term anticoagulation should be determined primarily by the patient's thromboembolic risk rather than the apparent success of ablation.

This remains an important principle because successful restoration of sinus rhythm does not guarantee permanent freedom from atrial fibrillation or eliminate other stroke-related risk factors.

However, recent randomized clinical trials have provided new evidence concerning carefully selected patients who remain free from documented atrial arrhythmia recurrence after catheter ablation.

What the ALONE-AF and OCEAN Trials Actually Showed

The ALONE-AF trial, published in JAMA in 2025, enrolled 840 patients who had undergone catheter ablation and had no documented atrial arrhythmia recurrence for at least one year.

Participants had at least one non-sex-related stroke-risk factor and were randomly assigned either to discontinue oral anticoagulation or to continue treatment with a direct oral anticoagulant.

At two years, the primary composite outcome of stroke, systemic embolism, or major bleeding occurred in 0.3% of patients assigned to discontinue anticoagulation and 2.2% of those assigned to continue treatment.

The difference was driven primarily by fewer major bleeding events.

Ischemic stroke occurred in 0.3% of the discontinuation group and 0.8% of the continuation group. These event rates were low, and the difference in ischemic stroke was not statistically conclusive.

The trial therefore provides important evidence concerning selected patients after successful ablation, but it does not establish that discontinuation carries no stroke risk or that the findings can be generalized to patients with substantially higher thromboembolic risk.

The OCEAN trial, published in The New England Journal of Medicine in January 2026, investigated a different antithrombotic strategy.

It enrolled 1,284 patients who had undergone apparently successful catheter ablation at least one year earlier and had defined stroke-risk factors. Participants were assigned to rivaroxaban or aspirin, with follow-up extending to approximately three years.

Rivaroxaban did not significantly reduce the trial's primary composite outcome of stroke, systemic embolism, or new covert embolic stroke compared with aspirin.

The primary outcome occurred at rates of 0.31 and 0.66 events per 100 patient-years, respectively. The difference was not statistically significant.

Fatal or major bleeding occurred in 1.6% of patients assigned to rivaroxaban and 0.6% of those assigned to aspirin. Although bleeding was numerically more frequent with rivaroxaban, the difference was not statistically conclusive.

These findings require careful interpretation.

Both trials involved selected post-ablation populations with relatively low observed thromboembolic event rates. Their results should not be generalized to everyone with atrial fibrillation, particularly those with higher stroke risk or documented arrhythmia recurrence.

The OCEAN findings also do not establish aspirin as a routine substitute for anticoagulation in patients with atrial fibrillation.

The broader evidence supporting oral anticoagulation for stroke prevention remains strong in patients with appropriate indications.

The emerging question is whether carefully selected patients who remain free from documented atrial fibrillation after successful ablation may sometimes benefit from a different long-term anticoagulation strategy.

How the 2026 Guidelines Interpret This Evidence

The 2026 Asia Pacific Heart Rhythm Society guidelines recognize that discontinuation of long-term anticoagulation may be considered in selected patients after catheter ablation.

Part II states that discontinuation may be considered when the estimated stroke risk is low, provided that comprehensive rhythm surveillance is established and the decision is reached through shared decision-making.

Part III further specifies that discontinuation may be considered in patients with low-to-intermediate stroke risk who have remained free from documented atrial arrhythmia recurrence for at least one year after ablation.

This is a Class IIb recommendation, supported by Level A evidence, meaning the option may be considered for selected patients rather than being recommended routinely.

The patient's underlying thromboembolic risk remains central to the decision.

Evidence concerning anticoagulant discontinuation is less reassuring in patients with higher stroke-risk scores. Continuing rhythm surveillance is also important because asymptomatic atrial fibrillation can recur.

A person should therefore not stop anticoagulation independently because palpitations have disappeared, a smartwatch displays a normal rhythm, or a recent electrocardiogram is reassuring.

Any decision about discontinuation requires specialist assessment, consideration of the available evidence, shared decision-making, appropriate rhythm monitoring, and a clear follow-up plan.

The possibility of stopping anticoagulation after successful ablation should be discussed as an individualized clinical decision, not as a guaranteed benefit of the procedure.

Coordinating Atrial Fibrillation Care in Viet Nam

Atrial fibrillation management frequently involves several aspects of healthcare delivered through different services.

A cardiologist may diagnose and treat the arrhythmia, while hypertension or diabetes is managed through primary care or another specialist clinic. Anticoagulant prescriptions may be reviewed during separate appointments, and advice on nutrition, physical activity, or sleep may come from additional healthcare professionals.

These arrangements can meet individual needs, but they also create opportunities for gaps in coordination.

A change in kidney function may be identified during one consultation without reaching the clinician responsible for anticoagulation.

A new medicine may be prescribed by another service without an appropriate review of potential interactions.

Someone may also receive advice to increase physical activity without a shared understanding of their current cardiac symptoms, treatment, or exercise limitations.

The integrated care framework promoted by the Asia Pacific Heart Rhythm Society provides a useful approach to addressing these challenges.

Its ABC pathway emphasizes avoiding stroke, better symptom management, and cardiovascular risk factor and comorbidity management.

For healthcare organizations in Viet Nam, this does not necessarily require establishing an entirely new atrial fibrillation center.

A practical starting point may be to review how essential clinical information, treatment decisions, and follow-up responsibilities are coordinated across existing services.

At diagnosis, patients need appropriate electrocardiographic confirmation, assessment of relevant cardiac and systemic conditions, evaluation of stroke and bleeding risks, and a clear explanation of the management plan.

Follow-up should then consider changes in symptoms, cardiovascular risk, kidney function, medication safety, and the continuing suitability of treatment.

Healthcare professionals from different disciplines may contribute according to their qualifications and authorized responsibilities.

Nurses may support patient education and follow-up. Pharmacists may help identify medication-related concerns and potential interactions. Qualified nutrition professionals may assist with weight and cardiometabolic management. Rehabilitation professionals may contribute to physical activity planning when clinically indicated.

These activities should form part of a coordinated care plan rather than operate independently of necessary cardiovascular assessment and treatment.

Viet Nam's Ministry of Health issued Decision No. 3312/QĐ-BYT on November 5, 2024, promulgating the professional document Guidelines for the Diagnosis and Treatment of Cerebral Stroke.

The document addresses atrial fibrillation as an important cause of cardioembolic stroke and includes guidance relevant to anticoagulation in secondary stroke prevention.

Its scope should be described accurately. It is a national stroke management guideline, not a comprehensive dedicated atrial fibrillation guideline or a formal Vietnamese adoption of the 2026 Asia Pacific Heart Rhythm Society recommendations.

International guidance can support professional education and clinical review, but its application must be considered alongside Vietnamese professional requirements, approved medicines, institutional protocols, and individual patient circumstances.

Access to treatment also affects continuity.

Medication costs, transportation, laboratory monitoring arrangements, continuity of prescriptions, and access to specialist assessment may influence whether patients receive appropriate long-term care.

These barriers should not be assumed to affect every patient or healthcare setting equally. Their importance needs to be understood through local service information and individual circumstances.

The 2026 regional guidelines recognize that differences in healthcare resources, cultural circumstances, and access to treatment influence the implementation of integrated care across the Asia-Pacific region.

For Viet Nam, the opportunity is to strengthen coordination and patient understanding within the existing healthcare system while developing locally relevant evidence about service delivery and outcomes.

Measuring the Quality of Atrial Fibrillation Care

Healthcare organizations may record how many patients with atrial fibrillation receive lifestyle counseling, have a stroke-risk score documented, or are prescribed anticoagulants.

These figures are useful, but they do not independently demonstrate that care has become safer or more effective.

A documented risk assessment may not lead to appropriate treatment. A patient may receive an anticoagulant without adequate review of changing kidney function or interacting medicines.

Similarly, someone may complete a weight-management or exercise program without any assessment of whether their symptoms, functional capacity, or cardiovascular health have improved.

Evaluation should therefore connect clinical assessment with treatment decisions, continuity of care, and outcomes.

For stroke prevention, organizations can examine whether patients with appropriate indications receive suitable anticoagulation, whether contraindications and bleeding risks are addressed, and whether the treatment plan remains appropriate as clinical circumstances change.

Medication safety may be evaluated through appropriate dosing, monitoring, adherence support, review of interactions, and responses to adverse events.

For rhythm-related care, meaningful outcomes may include symptom burden, functional capacity, quality of life, and documented arrhythmia recurrence or burden when reliable monitoring is available.

Lifestyle-related outcomes may include changes in blood pressure, body weight when clinically relevant, exercise tolerance, tobacco exposure, and alcohol consumption.

These measures should be interpreted alongside clinical outcomes rather than used as substitutes for them.

A reduction in palpitations does not automatically establish an equivalent reduction in stroke risk. Similarly, achieving a weight-loss target does not prove that every component of cardiovascular care is effective.

Continuity of care also deserves attention.

A referral is not necessarily successful because it was issued. The patient needs to access the appropriate service, receive a suitable assessment or intervention, and have relevant findings communicated to the responsible clinical team.

Particular attention may be needed when a patient moves between healthcare settings, undergoes a procedure, experiences an acute illness, or has medication changed by another provider.

Anticoagulation deserves special attention during these transitions because incomplete medication information or poorly coordinated treatment changes may expose patients to preventable harm.

For healthcare organizations, the objective should be to determine whether essential clinical decisions are being made appropriately, communicated clearly, and reviewed when circumstances change.

Professional and Legal Considerations in Viet Nam

Lifestyle Medicine can contribute to atrial fibrillation care through appropriate risk factor management, health education, and support for sustainable behavior change.

However, education in Lifestyle Medicine does not independently authorize a person to diagnose atrial fibrillation, prescribe anticoagulants, modify antiarrhythmic treatment, interpret clinical risk scores for individualized treatment decisions, or determine whether anticoagulation can be discontinued.

These activities require appropriate professional qualifications, clinical competence, and legal authorization.

In Viet Nam, the Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, provides the principal legal framework governing medical examination, treatment, professional licensing, and healthcare facility responsibilities.

The Law on Disease Prevention No. 114/2025/QH15, effective July 1, 2026, also provides a broader legal context for preventing noncommunicable diseases and addressing relevant health risk factors.

These laws should not be interpreted as establishing independent clinical practice authority through Lifestyle Medicine education or professional certification.

International training, membership, or certification does not automatically expand an individual's authorized scope of medical practice in Viet Nam.

The same distinction applies to international clinical guidelines.

The 2026 Asia Pacific Heart Rhythm Society recommendations are important scientific and professional references. However, they do not automatically replace Vietnamese professional requirements or establish the regulatory approval, reimbursement status, or clinical suitability of particular medicines or procedures.

Any anticoagulant, antiarrhythmic medicine, or other prescription treatment must be considered according to the patient's clinical condition, the approved information for the specific product, and applicable Vietnamese requirements.

Healthcare organizations should also recognize their responsibilities concerning the collection and processing of personal health information.

The Law on Personal Data Protection No. 91/2025/QH15 and Government Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, establish relevant requirements concerning personal data processing and protection.

Where wearable-device information, electrocardiographic recordings, symptom reports, medication records, or other identifiable health data are collected, healthcare organizations need to consider applicable requirements concerning lawful processing, confidentiality, access, security, retention, and disclosure.

These obligations also remain relevant when information is shared between healthcare providers or processed through digital health platforms, according to the applicable legal requirements.

For professional education, the distinction between explaining evidence-based approaches and making individualized treatment decisions must remain clear.

Implications for the Vietnam Lifestyle Medicine Alliance

Atrial fibrillation provides a practical example of how Lifestyle Medicine can contribute to established medical care without replacing it.

Appropriate weight management, physical activity, blood pressure control, tobacco cessation, alcohol reduction, and attention to relevant sleep and psychological conditions can improve cardiovascular health and support atrial fibrillation management.

However, these interventions address different clinical problems and are supported by evidence of varying strength.

Some may reduce arrhythmia burden or recurrence. Others may improve associated cardiometabolic conditions. Their benefits should not automatically be interpreted as equivalent protection against stroke or as justification for discontinuing anticoagulation.

For the Vietnam Lifestyle Medicine Alliance (VLMA), the opportunity lies in helping healthcare professionals understand these distinctions through evidence-based education, scientific knowledge exchange, and responsible collaboration.

Educational resources could address the relationship between lifestyle risk factors and atrial fibrillation, exercise safety, weight management, alcohol and sleep-related risks, and the importance of distinguishing symptom control from thromboembolic risk.

Another relevant area is the patient-safety dimension of long-term anticoagulation, particularly adherence, medication-related communication, risk reassessment, and coordinated follow-up.

Such educational work would benefit from collaboration with appropriately qualified cardiovascular professionals and should remain consistent with Vietnamese professional and legal requirements.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. Its activities focus on evidence-based professional education, capability development, scientific knowledge exchange, and collaboration.

VLMA does not independently diagnose atrial fibrillation, prescribe or adjust anticoagulants, provide cardiac procedures, or make individualized decisions about stroke-prevention treatment.

Its intended contribution is to strengthen professional understanding and support the responsible interpretation and application of scientific evidence within authorized healthcare services.

Better Rhythm Control Is Not Complete Cardiovascular Protection

For someone living with atrial fibrillation, meaningful improvement may include fewer palpitations, better exercise tolerance, improved sleep, and greater confidence in everyday activities.

These changes matter because they can improve quality of life and make daily activities easier.

However, successful management of atrial fibrillation requires more than reducing symptoms or restoring sinus rhythm.

The person may still have hypertension, diabetes, heart failure, or other conditions influencing cardiovascular and thromboembolic risk. Anticoagulation may remain necessary even when atrial fibrillation appears well controlled.

Conversely, not every person with atrial fibrillation requires lifelong anticoagulation. Recent evidence and the 2026 Asia Pacific Heart Rhythm Society recommendations recognize that treatment may be reconsidered in carefully selected patients following successful catheter ablation, but only after appropriate specialist assessment and with suitable monitoring and follow-up.

The important distinction is that these decisions must reflect the patient's clinical risk, the available evidence, and individual circumstances rather than assumptions based on symptom improvement.

For healthcare professionals in Viet Nam, integrating Lifestyle Medicine into atrial fibrillation care offers an opportunity to strengthen coordinated cardiovascular management while supporting patients in making sustainable health-related changes.

The objective is not simply to encourage healthier habits. It is to ensure that lifestyle-related interventions contribute to a coherent clinical approach in which stroke prevention, anticoagulation safety, rhythm management, and meaningful patient outcomes remain central.

A person whose atrial fibrillation symptoms have improved deserves to understand what that improvement means, what risks may remain, and why some treatments still need to continue.

Lifestyle Medicine can help improve cardiovascular health and atrial fibrillation outcomes, but better rhythm control should never be confused with complete protection against stroke.

Selected References

1. Joung B, Krittayaphong R, Guo Y, et al. 2026 Asia Pacific Heart Rhythm Society Guidelines (Part I) on Epidemiology, Detection/Screening and Integrated Patient Care in Atrial Fibrillation. Journal of Arrhythmia. 2026;42(5). DOI: 10.1002/joa3.70495.

2. Chao TF, Lip GYH, Chan YH, et al. 2026 Asia Pacific Heart Rhythm Society Guidelines (Part II) on Stroke Prevention in Atrial Fibrillation. Journal of Arrhythmia. 2026;42(5). DOI: 10.1002/joa3.70491.

3. Chen M, Soejima K, Gunawardene M, et al. 2026 Asia Pacific Heart Rhythm Society Guidelines (Part III) on Rate and Rhythm Control in Atrial Fibrillation. Journal of Arrhythmia. 2026;42(5). DOI: 10.1002/joa3.70492.

4. Choi EK, Middeldorp ME, Ahn HJ, et al. 2026 Asia Pacific Heart Rhythm Society Guidelines (Part IV) on Comprehensive Lifestyle Risk Factor and Comorbidity Management in Atrial Fibrillation. Journal of Arrhythmia. 2026;42(5). DOI: 10.1002/joa3.70490.

5. Asia Pacific Heart Rhythm Society. Just Published: 2026 APHRS Guidelines on Atrial Fibrillation. Official announcement. October 27, 2026.

6. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio-Thoracic Surgery. European Heart Journal. 2024;45:3314–3414. DOI: 10.1093/eurheartj/ehae176.

7. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149–e156. DOI: 10.1161/CIR.0000000000001193.

8. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246–1254. DOI: 10.1001/jama.2025.14679.

9. Verma A, Birnie DH, Jiang C, et al. Antithrombotic Therapy After Successful Catheter Ablation for Atrial Fibrillation. New England Journal of Medicine. 2026;394(4):323–332. DOI: 10.1056/NEJMoa2509688.

10. Ministry of Health of Viet Nam. Decision No. 3312/QĐ-BYT Issuing the Professional Guideline for Diagnosis and Treatment of Cerebral Stroke. November 5, 2024.

11. Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH: Law on Medical Examination and Treatment. February 26, 2026.

12. National Assembly of Viet Nam. Law on Disease Prevention No. 114/2025/QH15. December 10, 2025. Effective July 1, 2026.

13. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025. Effective January 1, 2026.

14. Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing Selected Provisions and Implementation Measures of the Law on Personal Data Protection. December 31, 2025. Effective January 1, 2026.

15. Rea BL, Cheema S, Lanza S, et al. Lifestyle Medicine Core Competencies: 2025 Update. American Journal of Lifestyle Medicine. 2026;20(3):443–451. DOI: 10.1177/15598276251379821.

Editorial and Professional Scope Note

This article presents an educational and professional perspective of the Vietnam Lifestyle Medicine Alliance on the contribution and limitations of evidence-based Lifestyle Medicine in atrial fibrillation care, based on information reviewed through October 30, 2026.

It is intended for professional information, education, and scientific knowledge exchange. It does not constitute a clinical practice guideline, individualized medical advice, an atrial fibrillation diagnostic or treatment protocol, exercise prescription, anticoagulant recommendation, or authoritative interpretation of Vietnamese law.

Vietnam Lifestyle Medicine Alliance (VLMA) is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. VLMA is not a licensed medical examination or treatment facility, cardiology service provider, medical licensing authority, or healthcare accreditation organization. It does not independently diagnose atrial fibrillation, prescribe or adjust anticoagulants, perform cardioversion or catheter ablation, or make individualized decisions about stroke-prevention treatment.

Clinical assessment, diagnosis, prescribing, rhythm management, anticoagulation, and follow-up must be undertaken by appropriately qualified and authorized healthcare professionals and facilities within their applicable scopes of practice and in accordance with relevant Vietnamese requirements.

Lifestyle-related interventions should not delay or replace necessary cardiovascular assessment, indicated anticoagulation, medical treatment, specialist evaluation, or emergency care. Improvement in symptoms, restoration of sinus rhythm, or apparently successful catheter ablation does not independently establish that anticoagulant treatment can be discontinued.

Decisions concerning initiation, modification, interruption, or discontinuation of anticoagulants require individualized medical assessment and appropriate professional supervision.

International clinical guidelines, scientific studies, and professional frameworks are cited for educational purposes. Their inclusion does not imply that they automatically have regulatory force in Viet Nam or that VLMA has formally adopted, delivered, validated, endorsed, or certified any atrial fibrillation management or treatment program discussed in this article.

The illustrative patient situations are hypothetical and do not describe actual VLMA clinical activities or identifiable patients.